BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35989458)

  • 1. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
    Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
    Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
    Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
    Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
    Commander LA; Seif AE; Insogna IG; Rheingold SR
    Br J Haematol; 2010 Aug; 150(3):345-51. PubMed ID: 20528871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
    Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
    Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
    Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
    Shimony S; DeAngelo DJ; Luskin MR
    Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
    J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.